BofA Hikes Ascendis Pharma Price Target to $216 Affirms Buy...
Ascendis Pharma A/S (NASDAQ:ASND) is one of the best 52-week high stocks to buy, according to analysts. On June 9, BofA analyst Tazeen Ahmad reiterated a ‘Buy’ rating on the...
Tag: trial results
2 results found
Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat’s...
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is among the best NASDAQ stocks under $50 to buy. On Monday, analysts at TD Cowen reaffirmed their Buy rating on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), expressing...
